Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/05/22
Corcept (CORT) Completes Enrolment in Mid-Stage Weight Gain StudyZacks Investment Research • 04/05/22
Corcept Therapeutics Completes Enrollment in Phase 2 GRATITUDE Study of Miricorilant in Patients with Antipsychotic-Induced Weight GainGlobeNewsWire • 04/04/22
Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Recurrent, Platinum-resistant Ovarian CancerGlobeNewsWire • 03/30/22
Corcept (CORT) Up 5.8% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 03/17/22
Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/16/22
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2021 Audited Financial Results and Provides Corporate UpdateGlobeNewsWire • 02/15/22
Corcept Therapeutics to Announce Fourth Quarter and Full-year 2021 Financial Results, Provide Corporate Update and Host Conference CallGlobeNewsWire • 02/08/22
Will Corcept (CORT) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 02/03/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORTPRNewsWire • 01/28/22
Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Corcept Therapeutics Incorporated (CORT)Business Wire • 01/25/22
Wall Street Analysts See a 26% Upside in Corcept (CORT): Can the Stock Really Move This High?Zacks Investment Research • 01/06/22